AIDS Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
HIV/AIDS Therapy
New HIV/AIDS therapy study findings recently were published by investigators at Schering Plough Research Institute
November 3rd, 2008
A report, 'Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection,' is newly published data in The Journal of Infectious Diseases. "Vicriviroc (VCV) is a CCR5 antagonist with nanomolar activity against human immunodeficiency virus (HIV) replication in vitro and in vivo. We report the results of a phase II dose-finding study of VCV plus dual nucleoside reverse-transcriptase inhibitors (NRTIs) in the treatment-naive HIV-1-infected subjects," researchers in the United States report. "This study was a randomized, double-blind, placebo-controlled trial that began with a 14-day comparison of 3...
Source: AIDS Weekly (2008-11-03)
|
